CCM
COGT icon

Consonance Capital Management’s Cogent Biosciences COGT Stock Holding History

Consonance Capital Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-610,000
Closed -$6.85M – 40
2020
Q4 		$6.85M Buy
+610,000
New +$6.7M 0.64% 29

Other funds holding COGT

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Consonance Capital Management's COGT Position: Q1 2021 in Review

Consonance Capital Management sold out of Cogent Biosciences (COGT) in Q1 2021, closing a stake of 610,000 shares — an estimated $6.85M sold.

Consonance Capital Management first reported a position in COGT in Q4 2020 and held it in 1 quarter. The position peaked at $6.85M in Q4 2020. 69 funds tracked by Wall St. Rank hold COGT as of Q1 2021.

  • Consonance Capital Management reported no remaining Cogent Biosciences position as of Q1 2021 after selling out during the quarter.
  • Consonance Capital Management sold 610,000 Cogent Biosciences shares in Q1 2021, an estimated $6.85M.
  • Consonance Capital Management first reported a position in Cogent Biosciences in Q4 2020 and held it in 1 quarter.
  • Consonance Capital Management's Cogent Biosciences position peaked at $6.85M in Q4 2020.
  • 69 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2021.

Based on Consonance Capital Management's 13F filing for Q1 2021, filed 17 May 2021.